PDF(Pubmed)
Abstract：
Vaccines remain the cornerstone of medical prevention and are highly effective in reducing the risk of severe disease and death due to coronavirus disease 2019 (COVID-19). In the context of expanding the therapeutic armamentarium against COVID-19, molnupiravir (Lagevrio) and ritonavir-boosted nirmatrelvir (Paxlovid) were developed, constituting the first effective oral treatments against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In this narrative review, we retrospectively inquired into the clinical trials and real-world studies investigating the efficacy of these agents. Overall, clinical trials and real-world studies have demonstrated the efficacy of both agents in reducing hospitalization and death rates in COVID-19 patients. As per current recommendations, their use is suggested in patients with mild to moderate symptoms who are at high risk of developing severe disease. Nevertheless, limited data exist regarding their efficacy in specific subpopulations, such as immunocompromised patients, those with severe kidney disease, pregnant women, and children.
摘要：
疫苗仍然是医疗预防的基石，在降低2019年冠状病毒病(COVID-19)导致严重疾病和死亡的风险方面非常有效。在扩大针对COVID-19的治疗性医疗设备的背景下，开发了莫努比拉韦（Lagevrio）和利托那韦增强的尼马特雷韦（Paxlovid），构成第一个有效的口服治疗严重急性呼吸道综合症冠状病毒2（SARS-CoV-2）。在这篇叙述性评论中，我们回顾性调查了这些药物疗效的临床试验和真实世界研究.总的来说,临床试验和现实世界研究表明,这两种药物在降低COVID-19患者的住院率和死亡率方面均有疗效.根据目前的建议，建议在患有轻度至中度症状的患者中使用它们，这些患者患有严重疾病的风险很高。然而，关于它们在特定亚群中的疗效的数据有限，比如免疫功能低下的患者，那些患有严重肾脏疾病的人，孕妇,还有孩子.
